Prakash Deedwania

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study)
    John A Spertus
    Mid America Heart Institute and the University of Missouri, Kansas City, MO, USA
    Am Heart J 143:636-42. 2002
  2. ncbi Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers
    Prakash Deedwania
    Division of Cardiology, VACCHCS UCSF School of Medicine, University of California at San Francisco, Fresno, CA 93703, USA
    J Clin Hypertens (Greenwich) 13:52-9. 2011
  3. ncbi New oral anticoagulants in elderly patients with atrial fibrillation
    Prakash C Deedwania
    School of Medicine, University of California at San Francisco, Fresno, CA 93703, USA
    Am J Med 126:289-96. 2013
  4. ncbi Evidence-based therapy for heart failure
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Fresno Medical Education Program, University of California San Francisco, Fresno, CA 93703, USA
    Med Clin North Am 96:915-31. 2012
  5. ncbi The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus
    Joel A Lardizabal
    Department of Medicine, University of California in San Francisco Fresno MEP, 155 North Fresno Street, Fresno, CA 93701, USA
    Curr Cardiol Rep 12:464-71. 2010
  6. ncbi Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California, San Francisco, School of Medicine, Fresno, USA
    Am J Med 124:681-8. 2011
  7. ncbi Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome
    Prakash C Deedwania
    University of California at San Francisco, CA, USA
    J Renin Angiotensin Aldosterone Syst 7:S12-8. 2006
  8. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
  9. ncbi Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)
    Prakash C Deedwania
    Veterans Affairs Central California Health Care System, University of California San Francisco, Fresno, California, USA
    Am J Cardiol 99:1538-43. 2007
  10. ncbi Diabetes and vascular disease
    Prakash Deedwania
    Department of Medicine, VACCHCS UMC, UCSF Program at Fresno, 2615 E Clinton Ave, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 6:127-38. 2008

Detail Information

Publications49

  1. ncbi Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study)
    John A Spertus
    Mid America Heart Institute and the University of Missouri, Kansas City, MO, USA
    Am Heart J 143:636-42. 2002
    ....
  2. ncbi Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers
    Prakash Deedwania
    Division of Cardiology, VACCHCS UCSF School of Medicine, University of California at San Francisco, Fresno, CA 93703, USA
    J Clin Hypertens (Greenwich) 13:52-9. 2011
    ..Because of these effects, vasodilating β-blockers may represent a favorable option in the treatment of high-risk patients with hypertension...
  3. ncbi New oral anticoagulants in elderly patients with atrial fibrillation
    Prakash C Deedwania
    School of Medicine, University of California at San Francisco, Fresno, CA 93703, USA
    Am J Med 126:289-96. 2013
    ..Practical considerations for the use of long-term anticoagulation in elderly patients also are discussed...
  4. ncbi Evidence-based therapy for heart failure
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Fresno Medical Education Program, University of California San Francisco, Fresno, CA 93703, USA
    Med Clin North Am 96:915-31. 2012
    ....
  5. ncbi The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus
    Joel A Lardizabal
    Department of Medicine, University of California in San Francisco Fresno MEP, 155 North Fresno Street, Fresno, CA 93701, USA
    Curr Cardiol Rep 12:464-71. 2010
    ..In addition to their established roles in the primary prevention of CVD in patients with diabetes, RAS blockers might be considered a suitable therapeutic choice for preventing the development of frank diabetes in high-risk patients...
  6. ncbi Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California, San Francisco, School of Medicine, Fresno, USA
    Am J Med 124:681-8. 2011
    ....
  7. ncbi Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome
    Prakash C Deedwania
    University of California at San Francisco, CA, USA
    J Renin Angiotensin Aldosterone Syst 7:S12-8. 2006
    ....
  8. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
    ..However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes...
  9. ncbi Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)
    Prakash C Deedwania
    Veterans Affairs Central California Health Care System, University of California San Francisco, Fresno, California, USA
    Am J Cardiol 99:1538-43. 2007
    ....
  10. ncbi Diabetes and vascular disease
    Prakash Deedwania
    Department of Medicine, VACCHCS UMC, UCSF Program at Fresno, 2615 E Clinton Ave, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 6:127-38. 2008
    ..The components of comprehensive risk reduction strategy consist of lifestyle changes, glycemic control, control of dyslipidemia and hypertension...
  11. ncbi Trials and tribulations associated with angina and traditional therapeutic approaches
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California, San Francisco, School of Medicine, Fresno, California, USA
    Clin Cardiol 30:I16-24. 2007
    ..Available data from recent studies also suggest treatment with an angiotensin converting enzyme inhibitor (ACEI), a statin and a regular exercise regimen in patients with stable CAD and angina pectoris...
  12. ncbi Clinical efficacy and cost-effectiveness of rosuvastatin
    Prakash C Deedwania
    University of California, Division of Cardiology, Department of Medicine, VA Central California Health Care System, UCSF Medical Education Program, 2615 East Clinton Avenue 111, Fresno, CA 93703, USA
    Expert Rev Pharmacoecon Outcomes Res 7:31-9. 2007
    ....
  13. ncbi Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials
    Prakash Deedwania
    Veterans Affairs Central California Health Care System University of California San Francisco, 2615 East Clinton Avenue, Fresno, California 93703, USA
    Am J Cardiol 104:3E-9E. 2009
    ..This article presents an overview of statin clinical trials and discusses implications for the clinical management of patients with low HDL cholesterol levels and increased cardiovascular risk...
  14. ncbi Statins in heart failure
    Prakash C Deedwania
    Division of Cardiology, Veterans Affairs Central California Health Care System, University of California, San Francisco Program at Fresno, Fresno, CA 93703, USA
    Cardiol Clin 26:573-87. 2008
    ..It additionally discusses the ongoing controversy regarding the lipid paradox and possible mechanisms responsible for potential benefit of statin therapy in heart failure...
  15. ncbi The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism
    Prakash Deedwania
    Cardiology Division, VACCHCS UCSF School of Medicine, Fresno, San Francisco, California 93703, United States
    Int J Cardiol 131:305-12. 2009
    ..Additional long-term controlled studies with appropriate follow-up are warranted to confirm the clinical potential of this drug, particularly its effects on dyslipidemia and other cardiovascular endpoints...
  16. ncbi Coronary artery disease in South Asians: evolving strategies for treatment and prevention
    Prakash Deedwania
    UCSF School of Medicine, San Francisco 93703, USA
    Indian Heart J 57:617-31. 2005
  17. ncbi Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California San Francisco Medical Education Program, Fresno, 93703, USA
    Am J Med 118:939-47. 2005
    ..Three clinical trials are being conducted to test whether early pharmacotherapy can reduce or delay the incidence of diabetes, and their results may well begin to shift the treatment paradigm toward earlier intervention...
  18. ncbi Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation
    Prakash C Deedwania
    Cardiology Division, Veterans Affairs Central California Health Care System, CA, UCSF School of Medecine, San Francisco, USA
    Am J Cardiovasc Drugs 11:265-75. 2011
    ..This review provides an overview of the available data regarding the clinical usefulness of these agents...
  19. ncbi Avoid the rush to judgment in acute coronary syndromes
    Prakash Deedwania
    University of California, San Francisco, School of Medicine, USA
    Postgrad Med 118:11-4, 22. 2005
  20. ncbi Management of coronary artery disease in patients with type 2 diabetes mellitus
    Sundararajan Srikanth
    Veterans Affairs Central California Health Care System University of California San Francisco Program at Fresno, 2615 East Clinton Avenue, Fresno, CA 93703, USA
    Curr Cardiol Rep 9:264-71. 2007
    ..We also identify controversies and issues that currently remain unresolved...
  21. ncbi Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients
    Prakash Deedwania
    Cardiology Division, VACCHS University of California, San Francisco, Fresno, CA 93703, USA
    J Clin Hypertens (Greenwich) 9:883-8. 2007
    ..The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) is evaluating the cardioprotective effect of an ACE inhibitor (ramipril) plus an ARB (telmisartan) in high-risk patients...
  22. ncbi Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  23. ncbi An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs
    Prakash Deedwania
    Division of Cardiology, Veterans Administration Central California Healthcare System University of California, San Francisco, Fresno, CA, USA
    Rev Cardiovasc Med 13:e89-104. 2012
    ..Other newer anticoagulant agents also provide us with possible suitable alternatives to warfarin, and their clinical use will depend on the results from ongoing studies...
  24. ncbi Hypertension as a cardiometabolic risk
    Sundararajan Srikanth
    Department of Medicine, UCSF School of Medicine, San Francisco, Fresno, CA, USA
    Indian Heart J 62:394-401. 2010
    ..Thus, when evaluating an individual with high blood pressure, the presence of other cardiometabolic risk factors should be sought and treated appropriately...
  25. ncbi Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus
    Sundararajan Srikanth
    Division of Cardiology, VACCHCS CMC, UCSF Program at Fresno, Fresno, CA, USA
    Cardiol Clin 29:47-70. 2011
    ..Prevention of diabetes and delaying its onset should also be an important aspect in future health care strategy and research to confront the oncoming tsunami of CVD related to diabetes...
  26. ncbi Bedside evaluation of cardiac markers. Point-of-care testing can differentiate acute coronary syndromes
    Ezra A Amsterdam
    University of California, Davis, School of Medicine, USA
    Postgrad Med 118:15-6, 19-22. 2005
    ..The authors also explore the potential of point-of-care testing for cardiac injury markers in the timely and accurate identification of ACS...
  27. ncbi Role of medical versus interventional strategies to prevent coronary events in patients with stable coronary artery disease
    Enrique V Carbajal
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System University of California, San Francisco, Fresno Program, Fresno, CA 93703, USA
    Cardiol Clin 29:157-65. 2011
    ..In this article, the authors review the evidence regarding the role of medical versus interventional strategies in reducing the risk of future coronary events in patients with stable CAD...
  28. ncbi Dyslipidemia and lipid-lowering therapy in the elderly
    Prakash Deedwania
    VACCHCS UCSF Cardiology division, 2615 E Clinton Avenue, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 3:453-63. 2005
    ..With increasing life expectancy, it is critical for physicians to recognize the importance of detection and treatment of dyslipidemia in the elderly...
  29. ncbi Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics
    Vibhuti Singh
    Cardiology Division, VACCHCS/UCSF, Fresno, CA 93703, USA
    Curr Atheroscler Rep 8:32-40. 2006
    ..Preliminary data suggest the need for stricter goals and increasingly aggressive therapy for these special populations, including administrative and educational interventions...
  30. ncbi Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease
    Joel A Lardizabal
    Division of Cardiology, Department of Medicine, University of California San Francisco Fresno Medical Education Program, Fresno, CA 93701, USA
    Cardiol Clin 29:87-103. 2011
    ..The strategy of using high-intensity statin therapy as the initial treatment approach in high-risk individuals, rather than focusing on specific cholesterol levels alone, remains a subject of debate...
  31. ncbi Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach
    Sundararajan Srikanth
    Department of Medicine, VA Central California Health Care System/University Medical Center, University of California, San Francisco Program at Fresno, 2615 East Clinton Avenue, Fresno, CA 93703, USA
    Cardiol Clin 23:193-210. 2005
    ....
  32. ncbi An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation
    Prakash Deedwania
    Chief Cardiology Division, VACCHCS UCSF, Fresno, CA, USA
    Core Evid 7:49-59. 2012
    ..In addition, there are several other indirect factor Xa inhibitors and vitamin K antagonists under study presently. Results from these studies will provide us with information about possible alternatives to warfarin...
  33. ncbi Endothelium-dependent vasodilation is impaired in healthy offspring of hypertensive parents
    Anil Bharani
    Division of Cardiology, Department of Medicine, MGM Medical College and Maharaja Yeshwant Rao Hospital, Indore, Madhya Pradesh, India
    Indian Heart J 63:255-8. 2011
    ..The study was designed to determine whether impaired endothelium-dependent vasodilation is present in Indian normotensive offspring with hypertensive parents...
  34. ncbi Expanding roles for atorvastatin
    Vibhuti Singh
    University of South Florida, College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA
    Drugs Today (Barc) 44:455-71. 2008
    ..These newer indications for statins, atorvastatin in particular, as part of more aggressive secondary and primary prevention, are reviewed in this paper...
  35. ncbi Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory
    Richard A Kerensky
    Malcom Randall Veterans Affairs Medical Center and the University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 39:1456-63. 2002
    ..We sought to determine the underlying coronary anatomy and characterize the culprit lesion after non-Q-wave myocardial infarction (NQWMI)...
  36. ncbi Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, Royal Infirmary, Glasgow G4 OSF, U K
    Diabetes Care 29:1220-6. 2006
    ..The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes...
  37. ncbi Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
    Prakash Deedwania
    Anesthesiology 109:14-24. 2008
    ..Although firm guidelines will need to await completion of these clinical trials, the present statement also provides consensus recommendations for hyperglycemia management in patients with ACS on the basis of the available data...
  38. ncbi Treating non-ST-segment elevation ACS. Pros and cons of current strategies
    Enrique V Carbajal
    Cardiology Division Veterans Affairs Central California Health Care System, Fresno 93703, USA
    Postgrad Med 118:23-32. 2005
    ..Long-term aggressive management of established risk factors for CAD is unquestionably the most prudent and cost-effective therapeutic approach in the long-term management in patients recovering from NSTE-ACS...
  39. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
    ..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease...
  40. ncbi Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study
    James Shepherd
    University of Glasgow, Glasgow, United Kingdom
    J Am Coll Cardiol 51:1448-54. 2008
    ..This subanalysis of the TNT (Treating to New Targets) study investigates the effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease (CHD) with and without pre-existing chronic kidney disease (CKD)...
  41. ncbi Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    John J P Kastelein
    Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Circulation 117:3002-9. 2008
    ....
  42. ncbi Diastolic dysfunction and autonomic abnormalities in patients with systolic heart failure
    Phyllis K Stein
    Washington University School of Medicine, St Louis, MO 63108, USA
    Eur J Heart Fail 9:364-9. 2007
    ..Patients with systolic heart failure (SHF) often have concomitant diastolic dysfunction (DD). SHF is associated with decreased heart rate variability (HRV), but the impact of degree of DD on HRV in SHF is unclear...
  43. ncbi The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
    ..This was a retrospective analysis to determine the effect of diabetes on outcome in patients with advanced heart failure (HF), and to determine the effect of beta-blockade in patients with HF with and without diabetes mellitus...
  44. ncbi A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS
    Michael J Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute/NIH, 6701 Rockledge Drive, Room 8146, Bethesda, MD 20892-7936, USA
    J Card Fail 9:354-63. 2003
    ....
  45. ncbi How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)
    John Wikstrand
    Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Card Electrophysiol Rev 7:264-75. 2003
    ....
  46. ncbi What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
    Lars Gullestad
    Baerums Sykehus, Baerum, Norway
    J Am Coll Cardiol 45:252-9. 2005
    ..The goal of this study was to explore the question: what resting heart rate (HR) should one aim for when treating patients with heart failure with a beta-blocker?..
  47. ncbi Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
    Stephen S Gottlieb
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Circulation 105:1182-8. 2002
    ..beta-Blockade improves survival when administered over a long period of time to patients with heart failure. However, the time course of any possible deterioration during the titration phase has not been reported...
  48. ncbi Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments
    Mikhail Kosiborod
    Mid America Heart Institute and University of Missouri Kansas City, Kansas City, MO 64111, USA
    Circulation 115:1975-81. 2007
    ..We tested whether serial health status assessments with the Kansas City Cardiomyopathy Questionnaire (KCCQ) can identify patients at increased risk for mortality and hospitalization...
  49. ncbi Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials
    Gary A Ford
    Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle upon Tyne, England
    Stroke 38:2965-71. 2007
    ..We report our experience in elderly high-risk AF patients on ximelagatran compared with warfarin therapy...